Limits...
CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

View Article: PubMed Central - PubMed

ABSTRACT

CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or recurrence-free survival, irrespective of the model analysis. In addition, CD147/EMMPRIN overexpression predicted a high risk for chemotherapy drugs resistance. CD147/EMMPRIN is a central player in tumor progression and predicts a poor prognosis, including in patients who have received chemo-radiotherapy. Our results provide the evidence that CD147/EMMPRIN could be a potential therapeutic target for cancers.

No MeSH data available.


Related in: MedlinePlus

Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and disease free survival (DSS) in cancer patients, and to predict easier recurrence of drug resistance.Panel A, represents the association of CD147/EMMPRIN positive expression with worse DSS in multivariate model. Panels B, represents the potential of CD147/EMMPRIN positive expression to predict easier recurrence of drug resistance.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5016850&req=5

f5: Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and disease free survival (DSS) in cancer patients, and to predict easier recurrence of drug resistance.Panel A, represents the association of CD147/EMMPRIN positive expression with worse DSS in multivariate model. Panels B, represents the potential of CD147/EMMPRIN positive expression to predict easier recurrence of drug resistance.

Mentions: Quantitative analysis of five different studies, representing 1,031 patients, linked CD147/EMMPRIN overexpression with DSS in four different solid tumors, namely breast cancer2, colorectal cancer [24, 41], oral squamous cell carcinomas7 and cervical cancer16. Multivariate model analysis established that CD147/EMMPRIN expression was associated with a worse DSS (meta-HR = 1.83; 95% CI: 1.27–2.65) (Table 4; Fig. 5A). Similarly, univariate model analysis indicated that CD147 expression associated with worse DSS (meta-HR = 5.81; 95% CI: 4.16–7.46) (Table 4). This pattern was unchanged even in the subgroup analyses stratified by cancer type. Multivariate model analysis also identified the following associations with DSS: breast carcinoma (meta-HR = 1.70; 95% CI: 1.02–2.84), oral squamous cell carcinoma (meta-HR = 3.89; 95% CI: 1.11–13.71) and colorectal cancer (meta-HR = 2.30; 95% CI: 1.03–5.14). The only cancer for which we did not observe an association was uterine cervical carcinoma (meta-HR =1.23; 95% CI: 0.52–2.90) (Supplementary Figure 4).


CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis
Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and disease free survival (DSS) in cancer patients, and to predict easier recurrence of drug resistance.Panel A, represents the association of CD147/EMMPRIN positive expression with worse DSS in multivariate model. Panels B, represents the potential of CD147/EMMPRIN positive expression to predict easier recurrence of drug resistance.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5016850&req=5

f5: Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and disease free survival (DSS) in cancer patients, and to predict easier recurrence of drug resistance.Panel A, represents the association of CD147/EMMPRIN positive expression with worse DSS in multivariate model. Panels B, represents the potential of CD147/EMMPRIN positive expression to predict easier recurrence of drug resistance.
Mentions: Quantitative analysis of five different studies, representing 1,031 patients, linked CD147/EMMPRIN overexpression with DSS in four different solid tumors, namely breast cancer2, colorectal cancer [24, 41], oral squamous cell carcinomas7 and cervical cancer16. Multivariate model analysis established that CD147/EMMPRIN expression was associated with a worse DSS (meta-HR = 1.83; 95% CI: 1.27–2.65) (Table 4; Fig. 5A). Similarly, univariate model analysis indicated that CD147 expression associated with worse DSS (meta-HR = 5.81; 95% CI: 4.16–7.46) (Table 4). This pattern was unchanged even in the subgroup analyses stratified by cancer type. Multivariate model analysis also identified the following associations with DSS: breast carcinoma (meta-HR = 1.70; 95% CI: 1.02–2.84), oral squamous cell carcinoma (meta-HR = 3.89; 95% CI: 1.11–13.71) and colorectal cancer (meta-HR = 2.30; 95% CI: 1.03–5.14). The only cancer for which we did not observe an association was uterine cervical carcinoma (meta-HR =1.23; 95% CI: 0.52–2.90) (Supplementary Figure 4).

View Article: PubMed Central - PubMed

ABSTRACT

CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or recurrence-free survival, irrespective of the model analysis. In addition, CD147/EMMPRIN overexpression predicted a high risk for chemotherapy drugs resistance. CD147/EMMPRIN is a central player in tumor progression and predicts a poor prognosis, including in patients who have received chemo-radiotherapy. Our results provide the evidence that CD147/EMMPRIN could be a potential therapeutic target for cancers.

No MeSH data available.


Related in: MedlinePlus